Dose of nafamostat mesylate during continuous kidney replacement therapy in critically ill patients: a two-centre observational study

Abstract Background Nafamostat mesylate is an anticoagulant used for critically ill patients during continuous kidney replacement therapy (CKRT), characterised by its short half-life. However, its optimal dosage remains unclear. This study aimed to explore the optimal dosage of nafamostat mesylate d...

Full description

Bibliographic Details

Published in:	BMC Nephrology
Main Authors:	Shinya Kameda, Akinori Maeda, Shun Maeda, Yutaro Inoue, Kazunari Takahashi, Akira Kageyama, Kent Doi, Tomoko Fujii
Format:	Article
Language:	English
Published:	BMC 2024-02-01
Subjects:	Acute kidney injury Continuous kidney replacement therapy Nafamostat mesylate Filter life Anticoagulant Dose
Online Access:	https://doi.org/10.1186/s12882-024-03506-0